High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Clinical trial NCT03945591 · COMPLETED
Trial details
- NCT number
- NCT03945591
- Sponsor
- NYU Langone Health
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-20
- Primary completion
- 2022-12-29
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.